Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure

被引：45
|
作者：
Prebet, Thomas [1 ,2 ,3 ]
Gore, Steven D. [1 ,3 ]
Thepot, Sylvain [3 ]
Esterni, Benjamin [2 ]
Quesnel, Bruno [3 ]
Rauzy, Odile Beyne [3 ]
Dreyfus, Francois [3 ]
Gardin, Claude [3 ]
Fenaux, Pierre [3 ]
Vey, Norbert [2 ,3 ]
机构：
[1] Johns Hopkins Univ, Sidney Kimmel Canc Ctr, Dept Hematol Malignancies, Baltimore, MD 21218 USA
[2] Inst J Paoli I Calmettes, Dept Hematol, F-13009 Marseille, France
[3] Grp Francophone Myelodysplasies, Bobigny, France
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2012年 / 157卷 / 06期
关键词：
Myelodysplasia; acute myeloid leukaemia; azacitidine; relapse; outcome; CONVENTIONAL CARE REGIMENS;
D O I：
10.1111/j.1365-2141.2012.09076.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：764 / 766
页数：3
相关论文
共 50 条
  • [21] Management of acute myeloid leukaemia following myelodysplastic syndrome in a kidney graft recipient
    Würthner, J
    Rump, LC
    Grotz, W
    Engelhardt, R
    Lübbert, M
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 1999, 14 (02) : 501 - 506
  • [22] Differentiation syndrome in acute myeloid leukemia after treatment with azacitidine
    Laufer, Christin B.
    Roberts, Owen
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2015, 95 (05) : 484 - 485
  • [23] Azacitidine A Review of its Use in the Management of Myelodysplastic Syndromes/Acute Myeloid Leukaemia
    Keating, Gillian M.
    DRUGS, 2012, 72 (08) : 1111 - 1136
  • [24] Models to study myelodysplastic syndrome and acute myeloid leukaemia
    Chao, Clifford
    Martinez, Isabella G.
    Wagenblast, Elvin
    CURRENT OPINION IN HEMATOLOGY, 2025, 32 (02) : 87 - 92
  • [25] InfliximabColonic extramedullary myeloid leukaemia, acute myeloid leukaemia and myelodysplastic syndrome: case report
    Reactions Weekly, 2016, 1628 (1) : 183 - 183
  • [26] Outcome of Patients with Lower-Risk Myelodysplastic Syndrome (MDS) After Azacitidine (AZA) Treatment Failure.
    Mishra, Asmita
    Lancet, Jeffrey E.
    Al Ali, Najla H.
    Padron, Eric
    Ho, Viet Q.
    Little, Bryan J.
    Pinilla-Ibarz, Javier
    List, Alan F.
    Komrokji, Rami S.
    BLOOD, 2012, 120 (21)
  • [27] SINGLE CENTRE SURVIVAL OUTCOMES IN THE TREATMENT OF INTERMEDIATE AND HIGH-RISK MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKAEMIA WITH 5-AZACITIDINE
    Stringer, R.
    Rider, D. T.
    Newman, D. J.
    Grace, D. R.
    HAEMATOLOGICA, 2015, 100 : 725 - 726
  • [28] Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine
    Duong, Vu H.
    Bhatnagar, Bhavana
    Zandberg, Dan P.
    Vannorsdall, Emily J.
    Tidwell, Michael L.
    Chen, Qing
    Baer, Maria R.
    LEUKEMIA & LYMPHOMA, 2015, 56 (06) : 1718 - 1722
  • [29] Erratum to Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia
    G. M. Keating
    Drugs, 2012, 72 : 1578 - 1578
  • [30] Successful azacitidine based treatment of therapy related myelodysplastic syndrome with normal karyotype occurred after acute myeloid leukemia
    Saltarelli, F.
    Tatarelli, C.
    Spiriti, M. A. Aloe
    Naso, V.
    Bianchi, M. P.
    Bianchi, M. P.
    Conte, E.
    Proia, S.
    Ferrari, A.
    LEUKEMIA RESEARCH, 2013, 37 : S110 - S111
12345